Evidence map›Paper›PMID 31470867›Full record

ArticleRadiation oncology (London, England)2019

Transforming growth factor beta 1 levels predict echocardiographic changes at three years after adjuvant radiotherapy for breast cancer.

Hanna Aula, Tanja Skyttä, Suvi Tuohinen, Tiina Luukkaala, Mari Hämäläinen, Vesa Virtanen, Pekka Raatikainen, Eeva Moilanen, Pirkko-Liisa Kellokumpu-Lehtinen

Open access · goldAbstract read
In one paragraph

Article in Radiation oncology (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Observational
  2. Review
  3. Article
  4. Review
  5. Article
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Hanna AulaFaculty of Medicine and Health Technology, Tampere University, 33014, Tampere, Finland. hanna.aula@tuni.fi.ORCID http://orcid.org/0000-0001-7680-517X
Tanja SkyttäFaculty of Medicine and Health Technology, Tampere University, 33014, Tampere, Finland.
Suvi TuohinenHeart Hospital, Tampere University Hospital, PO Box 2000, 33521, Tampere, Finland.
Tiina LuukkaalaResearch, Innovation and Development Center, Tampere University Hospital, PO Box 2000, 33521, Tampere, Finland.
Mari HämäläinenThe Immunopharmacology Research Group, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, 33014, Tampere, Finland.
Vesa VirtanenHeart Hospital, Tampere University Hospital, PO Box 2000, 33521, Tampere, Finland.
Pekka RaatikainenDepartment of Cardiology, Heart and Lung Center, Helsinki University Hospital, PO Box 340, 00029 HUS, Helsinki, Finland.
Eeva MoilanenThe Immunopharmacology Research Group, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, 33014, Tampere, Finland.
Pirkko-Liisa Kellokumpu-LehtinenFaculty of Medicine and Health Technology, Tampere University, 33014, Tampere, Finland.
Tampere University · FIHelsinki University Hospital · FITampere University Hospital · FITampere University of Applied Sciences · FI

Funding

Ida Montin Fund 20180260Paulo Foundation -Seppo Nieminen Fund 150620Seppo Nieminen Fund 150636the competitive state financing of the expert responsibility area of the Tampere University Hospital -the Finnish Society for Oncology -
6 · The paper itself

Abstract

backgroundTransforming growth factor beta 1 (TGF-β1) and platelet-derived growth factor (PDGF) are cytokines involved in fibrotic processes causing radiotherapy (RT)-induced cardiovascular changes. We aimed to investigate the associations between TGF-β1 and PDGF and the echocardiographic changes that occur during RT and during three-year follow-up.

methodsThe study included 63 women receiving adjuvant RT for early-stage breast cancer or ductal carcinoma in situ. Serum TGF-β1 (ng/ml) and PDGF (ng/ml) levels were measured by enzyme-linked immunoassay and echocardiographic examination was performed before RT, after RT and at 3 years. Patients were grouped by biomarker behavior by a trajectory analysis.

resultsTGF-β1 decreased from 19.2 (IQR 17.1-22.3) before RT to 18.8 (14.5-22.0) after RT (p = 0.003) and the decrease persisted at 17.2 (13.7-21.2) 3 years after RT (p = 0.101). PDGF decreased from 15.4 (12.6-19.1) before RT to 13.8 (11.7-16.2) after RT, p = 0.001, and persisted at 15.6 (10.4-18.4) at 3 years, p = 0.661. The TGF-β1 level before RT (Spearman's rho 0.441, p < 0.001) and the three-year change in TGF-β1 (rho = - 0.302, p = 0.018) correlated with global longitudinal strain (GLS) in echocardiography at 3 years. In trajectory analysis, two TGF-β1 behavior groups were found. Group 1 had significantly higher TGF-β1 levels before RT, 25.6 (22.3-28.6), than group 2, 17.8 (15.9-19.9), p < 0.001. In multivariable analysis, TGF-β1 trajectory group 1 (β = 0.27, p = 0.013), left-sided breast cancer (β = 0.39, p = 0.001) and the use of aromatase inhibitors (β = 0.29, p = 0.011) were significantly associated with a worsening in GLS from before RT to 3 years.

conclusionAn elevated pretreatment TGF-β1 may predict RT-associated changes in echocardiography.

Indexed as

AgedBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingCardiovascular DiseasesEchocardiographyFemaleFibrosisHumansMiddle AgedPrognosisProspective StudiesRadiotherapy, AdjuvantTransforming Growth Factor beta1TGFB1 protein, humanTransforming Growth Factor beta1Breast cancerCardiotoxicityEchocardiographyPlatelet-derived growth factorRadiotherapyTransforming growth factor beta 1

Identifiers

PMID31470867
PMCPMC6717329
OpenAlexW2971241819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.